Novel therapeutics for diabetes sourced from Northern Australian biota

Reference # H.5.2021062
Research Programs 5. Northern health service delivery and models of care

Project Timeframe 3 years (2021 to 2024)
CRCNA Funding $900,000
Total project value $2,276,796

Project summary and impacts

This project explored the potential of hookworm-derived molecules as a new class of biologic therapies for chronic disease. Building on evidence that hookworms can regulate immune responses and reduce inflammation, researchers identified and tested proteins produced by hookworms native to northern Australia as potential treatments for Type 2 diabetes.

The project combined drug discovery, laboratory research and preclinical testing to identify the most promising therapeutic candidates and evaluate their safety, effectiveness and suitability for further development. Using advanced research facilities at James Cook University, the team generated new knowledge about the therapeutic potential of worm-derived molecules and their role in treating metabolic and inflammatory diseases.

While the project initially focused on Type 2 diabetes, changing market conditions and the emergence of new diabetes treatments led Macrobiome Therapeutics to apply the platform to inflammatory bowel disease (IBD), where the underlying science showed strong potential. The research helped secure $2.8 million in follow-on private investment, enabling continued development of the technology and supporting the growth of a biotechnology company based in northern Australia.

The project also contributed to regional workforce development, supporting skilled research and technical jobs and strengthening northern Australia’s capability in biologics, immunology and biomedical innovation. By demonstrating how the region’s unique biodiversity can be translated into high-value health technologies, the project has helped lay the foundations for a growing biotechnology sector in northern Australia.